Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients

NCT00309088 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00309088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00309088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2006
Completion date
June 30, 2008
Enrollment
80 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis